Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.

Misato OkamuraKohei FujitaYuki YamamotoOsamu KanaiKoichi NakataniKanna HorimotoMasayuki HashimotoSatoru SawaiMaiko ShimosatoKazuya YoshidaTadashi Mio

Published in: Asia-Pacific journal of clinical oncology (2020)

The incidence of ARONJ was relatively high in lung cancer patients with bone metastases. When using antiresorptive agents, oncologists should closely monitor patients for ARONJ during the course of treatment and regularly consult with dentists, especially in patients receiving ICIs.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
patient reported outcomes
advanced cancer